Faehling, M. Et Al. 2020. First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC. ONCOLOGY RESEARCH AND TREATMENT , vol.43 , 120.

Faehling, M., Planchard, D., Cho, B. C., Gray, J. E., Paz-Ares, L. G., ÖZGÜROĞLU, M., ... Villegas, A. E.(2020). First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC. ONCOLOGY RESEARCH AND TREATMENT , vol.43, 120.

Faehling, Martin Et Al. "First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC," ONCOLOGY RESEARCH AND TREATMENT , vol.43, 120, 2020

Faehling, Martin Et Al. "First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC." ONCOLOGY RESEARCH AND TREATMENT , vol.43, pp.120, 2020

Faehling, M. Et Al. (2020) . "First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC." ONCOLOGY RESEARCH AND TREATMENT , vol.43, p.120.

@article{article, author={Martin Faehling Et Al. }, title={First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC}, journal={ONCOLOGY RESEARCH AND TREATMENT}, year=2020, pages={120} }